CARLSBAD, Calif.--(BUSINESS WIRE)-- Lineage Cell Therapeutics, Inc. (LCTX) (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell ...
LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology ...
Lineage Cell Therapeutics Inc. (NYSE:LCTX) is one of the best performing penny stocks to buy now. On September 9, HC Wainwright reiterated a ‘Buy’ rating on the stock and a $9 price target, buoyed by ...
Lineage Cell Therapeutics (LCTX) announced the receipt of an induced pluripotent stem cell line containing hypoimmunity edits, from Factor ...
LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology ...
Welcome to the Lineage Cell Therapeutics Second Quarter 2025 Conference Call. [Operator Instructions] An audio webcast of this call is available on the Investors section of Lineage's website at ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological ...
Lineage Cell Therapeutics has found an experienced hearing loss partner to advance a potentially novel transplant for auditory neurons. William Demant Invest, the largest shareholder of Danish hearing ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, ...
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q2 2025 Earnings Call Transcript August 12, 2025 Lineage Cell Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.13 EPS, expectations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback